The pill, not just the controversy, can have that affect on you. The FDA has just approved a labeling change for the cholesterol med that adds depression as a possible side effect. The same thing goes for Zetia, which along with Zocor comprises the Vytorin combo therapy.
In letters to Schering-Plough and Merck, which jointly market the meds, the agency says depression would be added to the section of the label that discusses adverse reactions in post-marketing and the new language will be included in a section of package inserts listing possible side effects. The section of the label being changed is for adverse reactions regardless of the "causality assessment."
A Merck spokesman told Dow Jones that the changes were made based on reports of depression by patients, which the drugmakers forwarded to the FDA, and caused them to submit proposed label changes in October.